Inovio Prices $17.5M Public Offering of 12.5M Shares at $1.40
Inovio Pharmaceuticals priced an underwritten offering of 12.5 million common shares with Series A and B warrants at $1.40 apiece, aiming to raise $17.5 million before discounts. The offering, managed by Piper Sandler, includes a 30-day option for up to 1.875 million additional share-warrant units.
1. Public Offering Structure
Inovio Pharmaceuticals is offering 12.5 million common shares along with Series A and Series B warrants, each exercisable for one share at $1.40, at a combined price of $1.40 per share-warrant package. Piper Sandler is acting as sole manager for the underwritten public offering.
2. Expected Proceeds and Timing
The company expects to raise approximately $17.5 million in gross proceeds before underwriting discounts, commissions and expenses, excluding any exercise of the 30-day underwriter option or accompanying warrants. The offering is expected to close on April 6, 2026, subject to customary closing conditions.